Company / Cash & Equivalents
Eloxx Pharmaceuticals, Inc. Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.1M
FY2025
5-year range
$1.1M / $6.1M
FY2021-FY2025
Trend
-81.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $1M over the past 10 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 10-year CAGR of -3.4%.
Declined from $2M to $1M over the past 10 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -3.4%
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 81.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | -81.4% |
| FY2016 | $6.1M | +281.4% |
| FY2015 | $1.6M | -19.9% |
| FY2014 | $2.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026